Abstract 929P
Background
The incidence of Laryngeal Squamous Cell Carcinoma (LSCC) has increased over the past 30 years, presenting new challenges in the management of this disease. In response to these evolving needs, we developed a machine learning (ML) prognostic model to optimize the treatment strategies for patients diagnosed with advanced LSCC.
Methods
Data from 2000 to 2020 were obtained from the SEER database. Patients who were not diagnosed based on histology, previous history of cancer or other concurrent malignancies, or unknown data were excluded. The chi-square test was used to compare variables. The Kaplan-Meier estimator, log-rank test, and Cox regression analysis identified prognostic factors for overall survival (OS) and cancer-specific survival (CSS). We constructed prognostic models using ML algorithms to predict 5-year survival. The data were randomly divided into training (70 %) and validation (30 %) sets. A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic curve was used to validate the accuracy and reliability of the ML models.
Results
A total of 7,350 patients were included: 2,689 with glottic (GC), 4,349 with supraglottic (SuGC), and 312 with subglottic (SG) cancers. The median patient age was 60 years. A total of 88.8% of the patients had a T3 and T4. The largest racial group was white, comprising 74.8% of the cases, and 21.1% of the cases were black. Most cases were stage IV AJCC (89.5%), and 41.4% of the patients had N2. Of the patients, 52% underwent total laryngectomy, which was the most common surgical procedure (39.1%). ML was used to identify the most important features of GC, including age, sex, and AJCC staging. Age and sex were considered as key factors for SuGC metastasis. For SC, the most important features identified were surgery combined with radiotherapy, sex, and surgery combined with chemoradiotherapy.
Conclusions
This study presents ML models tailored to three anatomical sites of LSCC. Key factors such as age and sex for GC and SuGC and treatment combinations for SG. These models underscore their utility in personalized medicine, enabling clinicians to customize treatment strategies based on individual characteristics and improve clinical outcomes.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
917P - Automatic characterization of spatial arrangement of tumor-infiltrating lymphocytes identifies oral cavity squamous cell carcinoma patients with poorer prognosis
Presenter: German Corredor
Session: Poster session 03
918P - Deciphering the molecular drivers behind locoregional progression, intratumoral heterogeneity, and clonal evolution in locally advanced head and neck cancer
Presenter: Gema Bruixola
Session: Poster session 03
919P - Predictive multi-omic signature in locally advanced laryngeal/hypopharyngeal (LH) squamous cell carcinoma (SCC) treated with induction chemotherapy (IC)
Presenter: Paolo Bossi
Session: Poster session 03
920P - Genomic landscape of head and neck cancer in Asia: A comprehensive meta-analysis of 1016 samples
Presenter: Sewanti Limaye
Session: Poster session 03
Resources:
Abstract
921P - Divergent fates: The ambiguous role of M2-like TAMs in oropharyngeal cancer
Presenter: Michael Saerens
Session: Poster session 03
922P - Genomic instability as a biomarker for advanced cancer of the head and neck
Presenter: Filippo Dall'Olio
Session: Poster session 03
923P - Tumor-informed ctDNA assay to predict recurrence in locally advanced SCCHN
Presenter: Natasha Honoré
Session: Poster session 03
924P - Claudin-1 (CLDN1) tight junction protein expression delineates distinct immune infiltrates in ascending (A) vs descending (D) subtypes of nasopharyngeal carcinoma: Potential implications for treatment selection
Presenter: Darren Wan-Teck Lim
Session: Poster session 03
925P - External validation of the CD8 radiomics signature as a prognostic marker in recurrent or metastatic head and neck cancer treated with nivolumab
Presenter: Laville Adrien
Session: Poster session 03
926P - Genetic alteration in olfactory neuroblastoma: Unraveling carcinogenesis mechanisms and chemotherapy resistance through whole exome sequencing analysis
Presenter: Haruhi Furukawa
Session: Poster session 03